Presently, the Civil Aviation Authority in the United Kingdom completely contraindicates pilots from flying while on isotretinion [1] . Additionally, following a month off the drug, an English pilot is required to have formal ophthalmologic assessment by the Civil Aviation Authority. The guidelines for flight surgeons in Canada restricts pilots to A3 category in which pilots using isotretinoin are restricted to fly with or as copilot only. The Federal Aviation Administration in the United States has restrictions that persons on the drug are not approved for night flying, but is presently reviewing if more restrictions are appropriate.
To be sure, ocular side effects can occur with isotretinoin, such as abnormal meibomian gland secretion, sicca, blepharoconjunctivitis, decreased tolerance to contact lenses, photophobia, and keratitis. However, such problems are short-lived and resolve spontaneously on discontinuation of the drug. There are some concerns regarding potentially persistent abnormalities such as corneal opacities, raised intracranial pressure, and retinal abnormalities, specifically night blindness. By electroretinograms, defects in night vision have been detected despite absence of subjective complaints by patients [2] . Moreover, such abnormalities have been demonstrated to persist as long as 8 years after cessation of isotretinoin [3, 4] . Indeed, there is now a query in the medical literature whether even one-time use of isotretinoin rules out a career in flying [4] . *Address correspondence to this author at the 600 Monroe Street, Suite 106B, Sylvania, Ohio 43560, USA; cgbakb@aol.com.
Of concern is if someone who has taken isotretinoin is ruled ineligible for commercial flying for life, might other professions which good night vision is required, such as truck driving, and ambulance drivers also become restrictive? Indeed, the Driver and Vehicle Licensing Agency may also eventually have a specific policy on the use of isotretinoin.
Inasmuch as isotretinion may affect night vision by interfering with the retinol pathway essential to the function of photoreceptors, it would be prudent for studies to be initiated to assess whether lower doses of isotretinion can be utilized without compromising night vision. Especially in light that dosing of isotretinion even at 10 mg per day for the 5-month duration of therapy is almost equally effective as 1-2 mg/kg dosing by some observers [5] , we must proceed to protect the interests (and future possible occupations) of our patients who need the drug before additional restrictions and limitations are unwisely applied.
